Skip to content

Alamar Biosciences

US · ALMR #2657 by market cap Listed 2026
26.48 -2.20 -7.67%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 7.05 Expensive vs history 77th percentile
5-year average -1.85 · #104 of 126 in Medical Devices
P/E ratio -26.77 Expensive vs history 97th percentile
5-year average -40.19 · forward -29.87
P/S ratio 18.77 Cheap vs history 28th percentile
5-year average 19.80 · forward 13.82 · #125 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Alamar Biosciences (ALMR) 1.84B -23.01 6.06 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value26.55 Economic moatNone UncertaintyHigh

Trading 0.3% below Morningstar's fair value estimate.

Fair value

Alamar Biosciences Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 16% premium over our quantitative fair value estimate of $26.55 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's lack of profitability weakens our estimated fair value. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's earnings yield of -3.5% ranks in the bottom 20% compared with global peers. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The firm's liquidity is an additional cause for concern. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, for example, sits in the top 40% globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This characteristic further promotes our unfavorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Alamar Biosciences discussion 0 comments

Add a comment